Switching from Neuren Pharma (NEU) to Telix Pharma (TLX) in our balanced portfolio, capitalizing on Telix’s innovative cancer treatment advancements and market potential.
Australia’s CPI drops to 4.9% in October, lower than expected, sparking a rally in interest rate-sensitive stocks and stabilizing the Australian dollar.
Equities closed higher Tuesday, underpinned by a fall in Treasury yields as dovish remarks from some Federal Reserve officials boosted bets on rate cuts.
This website provides general advice that does not take into account your individual objectives, financial situation, or needs. Past performance does not guarantee future results. The trade recommendations in our Pilot Portfolios are hypothetical, may exclude certain fees, and are not a basis for future investment decisions. Please do not rely solely on this information. We recommend seeking appropriate financial, taxation, and legal advice before making any investment decisions. Please refer to our Financial Services Guide for more information about our services.